Apr 1, 2023 · Carelon Medical Benefits Management clinical appropriateness guidelines and cancer treatment pathways

Mar 9, 2019 · Carelon Medical Benefits Management clinical appropriateness guidelines and cancer treatment pathways

The AIM Clinical Appropriateness Guidelines (hereinafter “the AIM Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. As used by AIM, the Guidelines establish objective and

Carelon Medical Benefits Management MFT B2B File Exchange. (required) (required)

Support Portal English (US) Representatives

Nov 6, 2022 · AIM Specialty Health disclaims any responsibility for the completeness or accuracy of the information contained herein. CLINICAL APPROPRIATENESS GUIDELINES ADVANCED IMAGING Appropriate Use Criteria: Oncologic Imaging ARCHIVED DECEMBER 18, 2022 for commercial, Medicare, and non-Anthem Medicaid

Check here to skip this screen and always use Native Client.

Mar 6, 2022 · This document has been archived because it has outdated information. It is for historical information only and should not be consulted for clinical use. Current versions of guidelines are available on the AIM Specialty Health website at http://www.aimspecialtyhealth.com/

Jul 8, 2021 · On March 23, 2022, the FDA approved the therapeutic radiopharmaceutical agent Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for treatment of metastatic prostate cancer detected on prostate-specific …

May 1, 2021 · AIM reviews all of its Guidelines at least annually. AIM makes its Guidelines publicly available on its website twenty-four hours a day, seven days a week. Copies of the AIM Clinical Appropriateness Guidelines are also available upon oral or written request.